IsoRay (ISR) Reports Prelim. Q2 Revenue of $1.54M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/26/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
IsoRay Announces Preliminary Second Quarter F2018 Revenue of $1.54 Million, 50% Year-over-Year Increase
January 24, 2018 8:01 AM EST
RICHLAND, Wash, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Â -- IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced preliminary unaudited revenue and gross profit results for the second quarter of fiscal 2018 ended December 31, 2017.
Preliminary revenue and gross profit for the second quarter of fiscal 2018:
Preliminary revenue for the three months ended December 31,... More
